IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Given Average Recommendation of “Moderate Buy” by Brokerages

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) has received an average rating of “Moderate Buy” from the seventeen brokerages that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and fifteen have assigned a buy rating to the company. The average 12 month target price among analysts that have covered the stock in the last year is $46.60.

Several equities research analysts have weighed in on the company. The Goldman Sachs Group upped their target price on IDEAYA Biosciences from $27.00 to $30.00 and gave the stock a “neutral” rating in a research note on Tuesday, October 21st. Weiss Ratings restated a “sell (d-)” rating on shares of IDEAYA Biosciences in a research report on Thursday. UBS Group assumed coverage on IDEAYA Biosciences in a research report on Wednesday, January 7th. They issued a “buy” rating and a $50.00 target price on the stock. Wall Street Zen raised IDEAYA Biosciences from a “hold” rating to a “buy” rating in a research note on Sunday, November 9th. Finally, BTIG Research reissued a “buy” rating and issued a $62.00 target price on shares of IDEAYA Biosciences in a report on Tuesday, October 21st.

IDEAYA Biosciences Stock Down 0.9%

IDYA stock opened at $34.47 on Tuesday. The company’s 50-day moving average price is $35.01 and its two-hundred day moving average price is $29.41. The firm has a market cap of $3.02 billion, a P/E ratio of -18.53 and a beta of 0.05. IDEAYA Biosciences has a 12 month low of $13.45 and a 12 month high of $39.28.

IDEAYA Biosciences (NASDAQ:IDYA) last posted its quarterly earnings results on Tuesday, November 4th. The company reported $1.33 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.12) by $1.45. The firm had revenue of $207.83 million for the quarter, compared to analyst estimates of $59.98 million. Equities analysts predict that IDEAYA Biosciences will post -3.07 EPS for the current year.

Institutional Trading of IDEAYA Biosciences

A number of hedge funds have recently added to or reduced their stakes in the stock. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of IDEAYA Biosciences by 25.7% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,260 shares of the company’s stock worth $147,000 after buying an additional 872 shares in the last quarter. KBC Group NV grew its position in IDEAYA Biosciences by 34.5% during the 4th quarter. KBC Group NV now owns 3,608 shares of the company’s stock worth $125,000 after acquiring an additional 925 shares during the last quarter. Farther Finance Advisors LLC grew its position in IDEAYA Biosciences by 171.1% during the 4th quarter. Farther Finance Advisors LLC now owns 919 shares of the company’s stock worth $32,000 after acquiring an additional 580 shares during the last quarter. Palumbo Wealth Management LLC increased its holdings in IDEAYA Biosciences by 60.6% in the 4th quarter. Palumbo Wealth Management LLC now owns 28,024 shares of the company’s stock worth $969,000 after purchasing an additional 10,572 shares in the last quarter. Finally, Aberdeen Group plc raised its position in IDEAYA Biosciences by 0.5% in the fourth quarter. Aberdeen Group plc now owns 560,623 shares of the company’s stock valued at $19,381,000 after purchasing an additional 2,575 shares during the last quarter. Institutional investors and hedge funds own 98.29% of the company’s stock.

About IDEAYA Biosciences

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.